17,261 trials
Pain, Postoperative
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 33; 47 Participants
Brain and Central Nervous System Tumors
Primary: Overall Survival — 13.2 Months
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response (Complete Response [CR]/Partial Response [PR]) Based on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)…
Gastric Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Docetaxel When Given in Combination With Oxaliplatin and Fluorouracil (Phase I) — 50 mg/m2
Dengue
Primary: N Antibody, Geometric Mean Titer(GMT) to Dengue Serotypes 1, 2, 3 and 4 — 2; 2; 2; 13 GMT value
Dyslipidemias
Primary: Percent Change From Baseline to 12 Weeks in High Density Lipoprotein Cholesterol (HDL-C) and Low Density Lipoprotein Cholesterol (LDL-C) With LY2484595 and Placebo…
Alcoholic Hepatitis
Primary: Survival at Day 29 of the Assigned Treatment — 2; 0; 1; 1 Participants
Psoriasis · Plaque Psoriasis
Primary: Change in Overall Disease Severity (ODS) Score — 52.2; 0.0 percentage of participants — p=<0.0001
Pain, Phantom · Pain, Neuropathic
Primary: Number of Patients With Chronic Post-amputation Pain — 37; 36 Participants — p=0.53
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) at the Specified Dose Level — 10; 11; 7; 6 Participants
Prostate Cancer
Primary: Percentage of Patients With PSA Doubling Time >=3 Months. — 55.8 % of patients with PSA-DT>= 3 months
End Stage Renal Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered IV in Pediatric CKD-5HD Patients: Cmax. — 217; 114 microgram/deciliter
Pulmonary Hypertension
Primary: Pulmonary Vascular Resistance (PVR) — 64; 119; 67; 46 dyn*sec/cm^5
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative · Chronic Myelomonocytic Leukemia · de Novo Myelodysplastic Syndrome
Primary: Number of Patients With HCT Failure. — 4; 0; 0; 5 Participants
Chronic Lymphocytic Leukemia · CLL
Primary: Overall Response Rate (ORR) — 25 Participants